Recent studies have indicated a role of complement in regulating T cell immunity but the mechanism of action of complement in this process remains to be clarified. Here we studied mice deficient in decay-accelerating factor (DAF), a key membrane complement regulator whose deficiency led to increased complement-dependent T cell immune responses in vivo. By crossing OT-II and OT-I T cell receptor transgenic mice with DAF-knockout mice, we found that lack of DAF on T cells did not affect their responses to antigen stimulation. Similarly, lack of DAF on antigen-presenting cells (APCs) of naïve mice did not alter their T cell-stimulating activity. In contrast, APCs from DAF-knockout mice treated with inflammatory stimuli were found to be more potent T cell stimulators than cells from similarly treated wild-type mice. Acquisition of higher T cell-stimulating activity by APCs in challenged DAF-knockout mice required C3 and C5aR and was correlated with decreased surface PD-L1 and/or increased CD40 expression. These findings implied that DAF suppressed T cell immunity as a complement regulator in the context of inflammation but did not play an intrinsic role on T cells or APCs. Collectively, our data suggest a systemic and indirect role of complement in T cell immunity.
Introduction
Decay-accelerating factor (DAF) is a glycosylphosphatidylinositol (GPI)-anchored cell surface regulator of complement activation. It inhibits complement activation by preventing the formation and accelerating the decay of C3/C5 convertases of both classical and alternative pathways 1 . DAF is widely expressed on mammalian cells where its role in preventing complement injury is well established 1, 2 . In humans, deficiency of DAF on blood cells contributes to the pathogenesis of paroxysmal nocturnal hemoglobinuria, a syndrome characterized by uncontrolled complement-mediated hemolysis and platelet activation 3, 4 . In mice, gene deletion studies have shown that DAFdeficient (Daf -/-) animals were more susceptible to complement-mediated inflammatory injury in several disease models including anti-glomerular basement membrane glomerulonephritis, ischemia reperfusion injury and lupus dermatitis [5] [6] [7] [8] .
In addition to its demonstrated activity in protecting host cells from complement attack, DAF has also been known to influence T cell immune responses in vivo. For example, when WT and Daf -/-mice were immunized with ovalbumin in complete
Freund's adjuvant , CD4 + T cells from Daf -/-mice were found to have an enhanced recall response to antigen re-stimulation and produced significantly higher levels of IFN-γ 9 .
Similar results in T cell reactivity were obtained when mice were immunized with a pathogenic myelin oligodendrocyte glycoprotein (MOG) peptide which caused a more severe form of experimental autoimmune encephalomyelitis in Daf -/-mice 9 . Likewise, in a model of CD8 + T cell immune response to lymphocytic choriomeningitis virus
For personal use only. on . by guest www.bloodjournal.org From infection, Daf -/-mice displayed a higher degree of CD8 + T cell expansion in their spleens and lymph nodes, had more numbers of antigen-specific CD8 + T cells and cleared the virus more quickly 10 . In other models involving skin and heart allograft transplantation experiments, deficiency of DAF from either the donor or the recipient mice elicited a more robust allogenic T cell immune response, leading to accelerated rejection of the transplanted organs 11, 12 While the phenotype of enhanced T cell immune response in Daf -/-mice has been demonstrated consistently, the mechanism by which DAF influences T cell immunity in vivo remains to be fully elucidated. As a GPI-anchored protein in lipid raft of the plasma membrane, DAF may participate in the signaling pathways of the T cell receptor (TCR) 13 . Additionally, by serving as a cellular ligand for CD97, an EGF-TM7 receptor upregulated rapidly on activated T cells, DAF could regulate T cell activation and differentiation through complement-independent mechanisms 14, 15 . On the other hand, the fact that enhanced T cell immune responses in Daf -/-mice required complement C3, and in many cases, C5a receptor (C5aR), supported a complement-dependent mechanism of action [9] [10] [11] [12] 16 . It is not clear, however, whether DAF played an intrinsic role on T cells or antigen-presenting cells (APCs) during cognate T cell/APC interaction or indirectly affected APC and T cell activation in vivo in the context of complement-mediated inflammation. In the present study, we have addressed this question by performing T cell activation experiments using DAF-sufficient and -deficient TCR transgenic T cells and naïve or activated APCs from WT and Daf -/-mice.
For personal use only. on . by guest www.bloodjournal.org From by a cell harvester (TOMTEC, Hamden, CT) and cell proliferation was measured by scintillation counting. In some experiments, purified T cells were activated by platebound anti-mouse CD3 mAb (5µg/ml) in the presence or absence of 2 µg/ml soluble antimouse CD28 mAb.
Materials and Methods

Mice and reagents
Daf
Analysis of cell surface markers
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Western blot analysis
Peritoneal macrophages were lysed in RIPA buffer and protein concentrations were determined by Bradford method. Total proteins (40 μg per well) were separated by SDS-PAGE under reducing conditions and then transferred to a polyvinylidene difluoride membrane (Millipore, Bedford, MA). The blot was probed with a polyclonal rabbit antimouse DAF antibody, and after stripping, was reprobed with a monoclonal anti-β-actin antibody. Signals were visualized by the ECL system (Amersham Bioscience, Piscataway, NJ) and detected by the FUJI image reader. 
Results
DAF does not play an intrinsic role on T cells during T cell activation. Previous
in vivo studies using different models have clearly shown that DAF deficiency in mice promoted T cell immunity and this phenotype was dependent on an intact complement system [9] [10] [11] [12] 16 . 
12
/-mice were more potent activators of TCR transgenic T cells than similarly elicited macrophages from WT mice (Fig 3B) . Unexpectedly, we found that in contrast to resident peritoneal macrophages, elicited peritoneal macrophages from Daf -/-and WT mice were both negative for DAF expression, suggesting that thioglycollate challenge caused complete down-regulation of DAF expression on WT mouse macrophages ( Fig   3C) . Thus, while DAF deficiency enhanced the APC activity of elicited peritoneal macrophages, such a phenotype was not correlated with DAF expression on macrophages at the time of T cell-APC interaction. Fig 4A and 4B) . Interestingly, we found that DCs isolated from LPS-treated 
Dendritic cells from lipopolysaccharide (LPS)-treated but not naive Daf
Daf
-/-mice were significantly more potent than DCs from similarly-treated WT mice in stimulating T cell activation (Fig 4B) . This effect of DAF deficiency on DC function apparently required an in vivo environment as no difference was observed between WT and DAF -/-DCs stimulated by LPS in vitro (data not shown).
Acquisition of higher T cell-stimulating activities by DAF -/-macrophages and DCs in vivo required C3 and C5aR
We next performed experiments to dissect the mechanism by which thioglycollate- 
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cell/DC culture) had no effect (Fig 5B) 
Discussion
There is accumulating evidence to support a role of complement in the regulation of T cell immunity, and studies of Daf -/-mice have proven to be particularly instructive in this regard. DAF is a GPI-anchored complement regulator on the host cell surface. Previous studies in our laboratory and by others have shown that Daf -/-mice displayed enhanced T cell immune responses in a variety of models including T cell-dependent autoimmunity, viral infection and allogeneic organ transplantation [9] [10] [11] [12] 16 . These studies have also established that the T cell immunity phenotype of Daf -/-mice was dependent on C3 and In separate experiments, we also revealed that DAF expression on resident peritoneal macrophages or splenic DCs from naïve mice had no effect on their activity to stimulate OT-II or OT-I T cells. Notwithstanding this, we found that thioglycollate-elicited For personal use only. on . by guest www.bloodjournal.org From
